SE9502167L - Insulinanalog-kompositioner - Google Patents

Insulinanalog-kompositioner

Info

Publication number
SE9502167L
SE9502167L SE9502167A SE9502167A SE9502167L SE 9502167 L SE9502167 L SE 9502167L SE 9502167 A SE9502167 A SE 9502167A SE 9502167 A SE9502167 A SE 9502167A SE 9502167 L SE9502167 L SE 9502167L
Authority
SE
Sweden
Prior art keywords
insulin analog
formulations
cresol
phenol
human insulin
Prior art date
Application number
SE9502167A
Other languages
Unknown language ( )
English (en)
Other versions
SE9502167D0 (sv
SE509052C2 (sv
Inventor
Diane Lee Bakaysa
David Nettleship Brems
Bruce Hill Frank
Henry Acken Havel
Allen Howard Pekar
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989969&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9502167(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SE9502167D0 publication Critical patent/SE9502167D0/sv
Publication of SE9502167L publication Critical patent/SE9502167L/sv
Publication of SE509052C2 publication Critical patent/SE509052C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE9502167A 1994-06-16 1995-06-14 Insulinanalog-hexamer-komplex SE509052C2 (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,634 US5474978A (en) 1994-06-16 1994-06-16 Insulin analog formulations

Publications (3)

Publication Number Publication Date
SE9502167D0 SE9502167D0 (sv) 1995-06-14
SE9502167L true SE9502167L (sv) 1995-12-17
SE509052C2 SE509052C2 (sv) 1998-11-30

Family

ID=22989969

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9502167A SE509052C2 (sv) 1994-06-16 1995-06-14 Insulinanalog-hexamer-komplex

Country Status (39)

Country Link
US (1) US5474978A (sv)
JP (2) JP3171541B2 (sv)
KR (1) KR100382326B1 (sv)
CN (1) CN1105576C (sv)
AT (1) AT408720B (sv)
BE (1) BE1009408A5 (sv)
BR (1) BR9502795A (sv)
CA (1) CA2151560C (sv)
CH (2) CH689250A5 (sv)
CO (1) CO4410203A1 (sv)
CZ (1) CZ287484B6 (sv)
DE (1) DE19521720B4 (sv)
DK (1) DK173015B1 (sv)
ES (1) ES2091727B1 (sv)
FI (1) FI118207B (sv)
FR (2) FR2721214B1 (sv)
GB (1) GB2291427B (sv)
GR (1) GR1003004B (sv)
HK (1) HK1015138A1 (sv)
HU (1) HU227240B1 (sv)
IE (1) IE68853B1 (sv)
IL (1) IL114151A (sv)
IT (1) IT1276723B1 (sv)
LU (1) LU88626A1 (sv)
MY (1) MY115631A (sv)
NL (1) NL1000566C2 (sv)
NO (1) NO322128B1 (sv)
NZ (1) NZ272359A (sv)
PE (1) PE19496A1 (sv)
PL (1) PL181310B1 (sv)
PT (1) PT101722B (sv)
RO (1) RO113530B1 (sv)
RS (1) RS49577B (sv)
RU (1) RU2152399C2 (sv)
SE (1) SE509052C2 (sv)
SI (1) SI9500200A (sv)
TW (1) TW421596B (sv)
UA (1) UA26874C2 (sv)
ZA (1) ZA954943B (sv)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498088A (en) * 1992-07-27 1996-03-12 Choate; John I. M. Keyboard arrangement to maximize typing speed and ease of transition from a qwerty keyboard
US5836705A (en) * 1992-07-27 1998-11-17 Choate; John I. M. Keyboard arrangement to maximize typing speed and data entry and to ease transition from a qwerty keyboard
US5352050A (en) * 1992-07-27 1994-10-04 Choate John I M Keyboard arrangement to maximize typing speed and ease of transition from a QWERTY keyboard
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
JPH11509195A (ja) * 1995-06-30 1999-08-17 ノボ ノルディスク アクティーゼルスカブ 糖尿病の特徴を有する疾患の予防
UA49890C2 (uk) * 1996-06-20 2002-10-15 Ново Нордіск А/С Водна інсулінова композиція, парентеральна фармацевтична композиція та спосіб поліпшення хімічної стабільності інсулінової композиції
PE79099A1 (es) 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
CN1276731A (zh) 1997-10-24 2000-12-13 伊莱利利公司 不溶性胰岛素组合物
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
DE69924232D1 (de) * 1998-01-09 2005-04-21 Novo Nordisk As Stabilisierte insulin-zubereitungen
US6635617B1 (en) 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
EP1121145B1 (en) * 1998-10-16 2002-04-17 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
CN1210058C (zh) * 1998-10-16 2005-07-13 诺沃挪第克公司 用于肺送递的稳定的浓缩胰岛素制剂
US6211144B1 (en) 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6489292B1 (en) 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
JP2002529514A (ja) * 1998-11-18 2002-09-10 ノボ ノルディスク アクティーゼルスカブ フェノール及びクレゾールを要さない安定なインスリン水性調製物
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
AU2001220765A1 (en) 2000-01-24 2001-07-31 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US7402571B2 (en) * 2000-07-31 2008-07-22 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
ES2664189T3 (es) 2002-01-09 2018-04-18 Emisphere Technologies, Inc. Polimorfos de 4-(4-cloro-2-hidroxibenzoil)aminobutanoato de sodio
US20030211976A1 (en) * 2002-03-07 2003-11-13 Andreasen Kasper Huus Polyamino acid-based particle insulin formulation
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
EA014887B1 (ru) 2003-06-17 2011-02-28 Сембайосиз Джинетикс Инк. Способ экспрессии инсулина в семенах растения, способ получения семян растений, содержащих инсулин, и растения, способные производить семена, содержащие инсулин
EP2085406A1 (en) * 2003-07-25 2009-08-05 ConjuChem Biotechnologies Inc. Long lasting insulin derivatives and methods thereof
WO2005072803A1 (en) * 2004-01-16 2005-08-11 Biodel, Inc. Sublingual drug delivery device
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
EP3058944B1 (en) 2004-05-06 2019-06-19 Emisphere Technologies, Inc. Crystalline polymorphic forms of monosodium n-[8-(2-hydroxybenzoyl)amino]caprylate
NZ551241A (en) * 2004-05-14 2010-08-27 Emisphere Tech Inc Aryl ketone compounds and compositions for delivering active agents
EP1750674A4 (en) * 2004-05-27 2012-05-23 Advanced Bionutrition Corp MICROPARTICLES FOR THE ORAL LEVY
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1773376A4 (en) 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JP2008509933A (ja) * 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
PL2918286T3 (pl) * 2004-10-05 2020-06-29 Novo Nordisk A/S Preparat farmaceutyczny zawierający insulinę w postaci krystalicznej, jak również w formie rozpuszczonej
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006093222A1 (ja) * 2005-03-02 2006-09-08 Ajinomoto Co., Inc. インスリンの多量体形成阻害剤
EP2452691A3 (en) 2005-08-29 2012-09-05 HealOr Ltd. Methods and compositions for prevention of diabetic and aged skin
BRPI0616558B1 (pt) 2005-09-19 2021-09-08 Emisphere Technologies, Inc Forma i do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, forma ii do sal dissódico do ácido n-(5-clorossaliciloil)-5-aminocapróico, solvato de etanol cristalino do sal dissódico do ácido n-(5-salicioloil)-8-aminocaprílico, forma iii do sal dissódico do ácido n-(5-clorossaliciloil)-5- aminocapróico, octahidrato do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, monohidrato cristalino do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, composição farmacêutica, processo para preparar a forma i do sal dissódico do ácido n-(5-saliciloil)-8-aminocaprílico, processo para preparar um solvato de monoetanol do sal dissódico do ácido n-(5-saliciloil)-8-(...)
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
JP2009527526A (ja) * 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
WO2008043033A2 (en) 2006-10-04 2008-04-10 Case Western Reserve University Fibrillation-resistant insulin and insulin analogues
EP3050568B1 (en) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Methods and compositions for the sustained release of chromium
JP5526018B2 (ja) * 2007-03-21 2014-06-18 エミスフェアー・テクノロジーズ・インク アリルオキシおよびアルキルオキシ安息香酸送達薬剤
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
AU2008313248B2 (en) 2007-10-16 2012-04-26 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
US8022048B2 (en) 2007-11-02 2011-09-20 Emisphere Technologies, Inc. Method of treating vitamin B12 deficiency
AU2009276346B2 (en) 2008-07-31 2014-07-03 Case Western Reserve University Halogen-stabilized insulin
US8354435B2 (en) 2008-09-08 2013-01-15 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
KR20110082180A (ko) 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND USES THEREOF
ES2791683T3 (es) 2009-01-28 2020-11-05 Smartcells Inc Sistemas a base de conjugados para la administración controlada de fármacos
JP2012517459A (ja) 2009-02-12 2012-08-02 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ 代謝障害治療のためのカルジオトロフィン１の使用
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
WO2010107519A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
CA2789972A1 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
AU2011220867B2 (en) * 2010-02-24 2014-05-15 Emisphere Technologies, Inc. Oral B12 therapy
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9309209B2 (en) 2010-09-30 2016-04-12 Solvay Sa Derivative of epichlorohydrin of natural origin
WO2012115641A1 (en) 2011-02-23 2012-08-30 Elona Biotechnologies Lis-pro proinsulin compositions and methods of producing lis-pro insulin analogs therefrom
US8933022B2 (en) 2011-03-01 2015-01-13 Jds Therapeutics, Llc Methods and compositions for the treatment and prevention Hypoglycemia and related disorders
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2771026A4 (en) 2011-10-27 2015-08-05 Univ Case Western Reserve QUICKLY ULTRA-CONCENTRATED INSULIN ANALOG FORMULATIONS
WO2014004278A1 (en) * 2012-06-26 2014-01-03 The Curators Of The University Of Missouri Photocleavable drug conjugates
EP2877200B1 (en) 2012-07-17 2019-05-08 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
CN104902922B (zh) 2012-11-13 2017-12-12 阿道恰公司 包含经取代阴离子化合物的速效胰岛素制剂
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
WO2014096985A2 (en) 2012-12-19 2014-06-26 Wockhardt Limited A stable aqueous composition comprising human insulin or an analogue or derivative thereof
JP2016505601A (ja) 2012-12-26 2016-02-25 ウォックハート リミテッド 医薬組成物
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
AR098168A1 (es) 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
MX2018009748A (es) 2016-02-11 2019-02-07 Nutrition 21 Llc Composiciones que contienen cromo para mejorar la salud y el estado físico.
AU2018275545B2 (en) 2017-06-01 2021-02-04 Eli Lilly And Company Rapid-acting insulin compositions
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
BR112022007593A2 (pt) 2019-10-25 2022-08-23 Cercacor Lab Inc Compostos indicadores, dispositivos que compreendem compostos indicadores e métodos de fabricação e uso dos mesmos
MX2022012208A (es) 2020-03-31 2022-12-15 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales.
AU2021382599A1 (en) 2020-11-19 2023-06-22 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
FI78616C (sv) * 1982-02-05 1989-09-11 Novo Industri As Förfarande för framställning av en för infusionsändamål avsedd stabili serad insulinlösning, som har en förhöjd zinkhalt
US4608634A (en) * 1982-02-22 1986-08-26 Texas Instruments Incorporated Microcomputer with offset in store-accumulator operations
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
EP0425482B1 (en) * 1988-07-20 1993-08-18 Novo Nordisk A/S Human insulin analogs and preparations containing them
JPH04502465A (ja) * 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK0705275T3 (da) * 1993-06-21 1999-09-20 Novo Nordisk As AspB28-insulin-krystaller
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
FR2721214B1 (fr) 1997-09-26
CN1122248A (zh) 1996-05-15
US5474978A (en) 1995-12-12
KR100382326B1 (ko) 2003-07-07
RS49577B (sr) 2007-04-10
SE9502167D0 (sv) 1995-06-14
IL114151A (en) 2000-09-28
DE19521720A1 (de) 1995-12-21
BE1009408A5 (fr) 1997-03-04
GB9512038D0 (en) 1995-08-09
PL181310B1 (pl) 2001-07-31
IT1276723B1 (it) 1997-11-03
NO952357L (no) 1995-12-18
CH689250A5 (de) 1999-01-15
NL1000566C2 (nl) 1996-12-03
RU2152399C2 (ru) 2000-07-10
FR2741078A1 (fr) 1997-05-16
NO322128B1 (no) 2006-08-21
UA26874C2 (uk) 1999-12-29
MY115631A (en) 2003-08-30
JP2001199899A (ja) 2001-07-24
SI9500200A (en) 1996-02-29
AT408720B (de) 2002-02-25
FR2741078B1 (fr) 1998-08-07
NO952357D0 (no) 1995-06-14
KR960000924A (ko) 1996-01-25
ATA101695A (de) 2001-07-15
FR2721214A1 (fr) 1995-12-22
DK173015B1 (da) 1999-11-15
HU9501716D0 (en) 1995-08-28
DE19521720B4 (de) 2009-09-03
CZ287484B6 (en) 2000-12-13
ITMI951278A1 (it) 1996-12-14
CA2151560C (en) 2000-05-09
RU95110109A (ru) 1997-05-10
GR950100229A (en) 1996-02-29
IE950436A1 (en) 1995-12-27
FI118207B (sv) 2007-08-31
FI952931A0 (sv) 1995-06-14
ES2091727A1 (es) 1996-11-01
TW421596B (en) 2001-02-11
JPH083067A (ja) 1996-01-09
ES2091727B1 (es) 1998-02-01
GB2291427A (en) 1996-01-24
HU227240B1 (en) 2010-12-28
HUT73186A (en) 1996-06-28
CH689935A5 (de) 2000-02-15
BR9502795A (pt) 1996-03-12
JP3171541B2 (ja) 2001-05-28
SE509052C2 (sv) 1998-11-30
AU694501B2 (en) 1998-07-23
PT101722B (pt) 1997-02-28
NZ272359A (en) 1996-10-28
CZ154295A3 (en) 1996-02-14
GB2291427B (en) 1998-09-16
CN1105576C (zh) 2003-04-16
NL1000566A1 (nl) 1995-12-18
IL114151A0 (en) 1995-10-31
FI952931A (sv) 1995-12-17
LU88626A1 (fr) 1996-02-01
RO113530B1 (ro) 1998-08-28
CA2151560A1 (en) 1995-12-17
ZA954943B (en) 1997-09-14
YU39695A (sh) 1997-08-22
PL309098A1 (en) 1995-12-27
PE19496A1 (es) 1996-06-01
ITMI951278A0 (it) 1995-06-14
GR1003004B (el) 1998-11-05
DK67795A (da) 1995-12-17
HK1015138A1 (en) 1999-10-08
AU2168095A (en) 1996-01-04
IE68853B1 (en) 1996-07-24
CO4410203A1 (es) 1997-01-09
PT101722A (pt) 1995-12-29

Similar Documents

Publication Publication Date Title
SE9502167L (sv) Insulinanalog-kompositioner
SE9502168D0 (sv) Insulinanalog-kompositioner
ATE247666T1 (de) Wasserlöslische prodrugs von 2,6- diisopropylphenol-analoga
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
AU747599C (en) Antitumor agents
BR9507758A (pt) Fração de copolímero-1 e composição para o tratamento de esclerose múltipla
EP0339237A3 (en) Phenol substituted gem-diphosphonate derivatives, process for their preparation and pharmaceutical compositions containing them
BG102215A (en) Compounds and pharmaceutical compositions containing them
BG103429A (en) Methods and compositions for neurone growth stimulation
DE69526120D1 (de) Verwendung von nebivolol als anti-atherogenisches mittel
DE69905170D1 (en) Thiazolopyrimidinderivate
DE69905368D1 (en) Oxydiertes thymosin beta 4
EP0975351A4 (en) TREATMENT OF MULTIPLE Sclerosis BY TAKING OR INHALING COPOLYMER-1
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
DE69814109D1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE272648T1 (de) Glycokonjugate von 20(s)-camptothecin
Przuntek et al. The protective effect of 1-tert. butyl-4, 4-diphenylpiperidine against the nigrostriatal neurodegeneration caused by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine
IT9020020A0 (it) "n,n'-ditrimetossibenzoilpiperazine 2-sostituite, procedimento per la loro preparazione e composizioni terapeutiche che le contengono
ATE160573T1 (de) 1,3.5 (10) - estratriene derivate mit oraler wirkung
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
AU4630599A (en) Perfume composition

Legal Events

Date Code Title Description
NUG Patent has lapsed